A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Dunn LA, Ho AL, Michel LS, Wong W, et al. Oral Oncol 2025;169:107524.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dunn LA, Ho AL, Michel LS, Wong W, et al. A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 2025;169:107524.
PMID: 40902554